ClinicalTrials.gg
Status unknownNCT06169228DAMOSAUpdated Dec 13, 2023

Mandibular Advancement Device on Sleep Quality in Obstructive Sleep Apnea Patients

An observational study in Sleep Apnea, Obstructive, sponsored by Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz. Status unknown at 1 site in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-12-13.

Sponsored by Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz · Observational

The sponsor has not verified this record recently (last verified Dec 2023), so the status shown — last known as Active, not recruiting — may be out of date.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
50
Ages
18 Years and older
Sex
All
01

Study summary

Sleep is an important factor that influences long-term quality of life with known health consequences. Obstructive sleep apnea, the most prevalent disease that disturbs sleep, is considered a public health problem. Treatment with continuous positive airway pressure is cost effective and reverses the clinical consequences but there is a percentage of patients who do not tolerate it or leave it without treatment and with potential future health complications. Mandibular advancement device can be a valid and well tolerated alternative, it is known that it reduces apnea-hypopnea index, but its effect on the improvement of sleep quality is evaluated by polysomnography that interferes with the quality of sleep. There is an ambulatory monitoring device for sleep quality and circadian rhythms, which can register prolonged periods of time, under natural conditions and at a lower cost than a polysomnography. This pilot project assesses whether mandibular advancement device is an effective and well tolerated alternative in the treatment of obstructive sleep apnea to improve the quality of life and sleep in the medium and long term.

Read the detailed description

Design: observational, unicentric prospective. 50 patients / year will be included, for 3 years. The care protocol (evaluation and follow-up) of the multidisciplinary sleep unit will be followed. Demographic and anthropometric data will be collected. The dental status of the temporo-mandibular joint will be assessed. Radiological records, home respiratory polygraphy, ambulatory monitoring device for 7 days , quality of life questionnaires before and after treatment.

02

Conditions studied

  • Sleep Apnea, Obstructive
03

In context

Sleep Apnea, Obstructive

2,263 studies on the registry are indexed under Sleep Apnea, Obstructive; 465 are open to participants now.

This study's enrollment of 50 is below the median of 105 across 666 observational studies indexed under Sleep Apnea, Obstructive.

Browse Sleep Apnea, Obstructive studies →

Lead sponsor

Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz is the lead sponsor of 74 studies on the registry; 25 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Patients who come to the Multidisciplinary sleep unit of the Fundación Jiménez Díaz with suspicion of Obstructive sleep apnea and who present an Apnea Hypopnea Index greater than five

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of Obstructive Sleep Apnea Syndrome
  • opt for mandibular advancement device as 1st treatment alternative
  • opt for mandibular advancement device due to intolerance to continuous positive airway pressure

Exclusion criteria

Exclusion Criteria:

  • Patient with orthodontics, malocclusion and periodontal or temporomandibular joint disease who, after assessment by dentistry contraindicates it.
  • Central Sleep apnea (more than 50% of central events in the baseline polygraph).
  • Under 18 years old.
  • Pregnancy
  • Comorbidities that can potentially alter sleep architecture.
  • Psychophysical inability to complete questionnaires.
  • Not obtaining informed consent.
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
50 participants (actual)
Patient registry
No
Biospecimen retention
Samples without dna

Interventions

  • Devicemandibular advancement

    The multidisciplinary sleep unit assessment and follow-up protocol will be followed for this group of patients based on the Spanish Clinical Practice Guideline of the Spanish Sleep Society (SES) on the use of mandibular advancement devices in the treatment of patients with obstructive sleep apnea

06

What researchers measure

Primary outcomes

  1. mandibular advancement device on sleep quality

    Tolerability and efficacy of treatment with a mandibular advancement device (MAD) on sleep quality in patients with Obstructive Sleep Apnea (OSA) measured by the ambulatory circadian monitoring device.

    Time frame: 3 years

  2. ambulatory circadian monitoring device

    To evaluate improvement in sleep quality with mandibular advancement devices measured by fragmentation and stability of sleep by the circadian monitoring sensor.

    Time frame: 3 years

  3. home sleep apnea test

    To evaluate the number of residual apneic breaths measured by home home sleep apnea test

    Time frame: 3 years

Secondary outcomes

  1. Obstructive sleep apnea severity

    Evaluate the severity by home sleep apnea test

    Time frame: 3 years

  2. questionnaire SF-12

    multidimensional health related quality of life

    Time frame: 3 years

  3. questionnaire EuroQoL

    standardized non-disease specific instrument to describe and value health-related quality of life

    Time frame: 3 years

  4. questionnaire iPAQ

    International Physical Activity Questionnaire

    Time frame: 3 years

07

Study locations

1 site
  • Maria Fernanda Troncoso Acevedo
    Madrid, 28004, Spain
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2021 to primary completion in Sep 2022, 20 months.

Of 259 non-industry observational studies under Sleep Apnea, Obstructive, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 60. This study's 20 months is below that.

Counting every sponsor, half of 294 studies reached it within 30 months; a quarter within 15 and three quarters within 60.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 30, 2023
First posted
Dec 13, 2023
StartActual
Jan 1, 2021
Primary completionActual
Sep 30, 2022
CompletionEst.
Dec 31, 2024
Last update
Dec 13, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 13, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06169228
Lead sponsor
Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz
Responsible party
Maria Fernanda Troncoso (Investigador principal, Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz) — Principal investigator
First posted
Dec 13, 2023
Start date
Jan 1, 2021
Primary completion
Sep 30, 2022
Completion
Dec 31, 2024 (estimated)
Last update
Dec 13, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Dec 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion